Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
1.00%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
-100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.38%
median of 720 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Cogent Biosciences, Inc.
Market Cap
$5.24B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.22B
Gross Margin
-6537.01%
TTM Avg
-3376.01%
3Y Avg
-7968.48%
5Y Avg
-11525.78%
Market Cap
$5.18B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
-67.67%
5Y Avg
-188.00%
Market Cap
$5.38B
Gross Margin
95.85%
TTM Avg
94.37%
3Y Avg
93.84%
5Y Avg
94.07%
Market Cap
$5.09B
Gross Margin
49.52%
TTM Avg
48.04%
3Y Avg
46.91%
5Y Avg
45.73%
Market Cap
$5.56B
Gross Margin
53.85%
TTM Avg
55.16%
3Y Avg
56.69%
5Y Avg
56.69%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | $5.24B | 0.00% | 0.00% | 0.00% | 0.00% |
| CRISPR Therapeutics AG (CRSP)vs › | $5.22B | -6537.01% | -3376.01% | -7968.48% | -11525.78% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.18B | 0.00% | 0.00% | -67.67% | -188.00% |
| Doximity, Inc. (DOCS)vs › | $5.36B | 88.07% | 89.65% | 88.97% | 88.20% |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.38B | 95.85% | 94.37% | 93.84% | 94.07% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.09B | 49.52% | 48.04% | 46.91% | 45.73% |
| Erasca, Inc. (ERAS)vs › | $5.08B | 0.00% | 0.00% | 0.00% | 0.00% |
| RadNet, Inc. (RDNT)vs › | $5.54B | 9.70% | 9.04% | 10.84% | 11.30% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.56B | 53.85% | 55.16% | 56.69% | 56.69% |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.90B | 81.70% | 78.24% | 78.79% | 67.54% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | -1503.53% |
| 2020-06-30 | -871.40% |
| 2020-03-31 | -35.09% |
| 2019-12-31 | 32.27% |
| 2019-09-30 | -913.24% |
| 2019-06-30 | -238.34% |
| 2019-03-31 | -277.01% |
| 2018-12-31 | 100.00% |
| 2018-09-30 | 100.00% |
| 2018-06-30 | 100.00% |
| 2018-03-31 | 100.00% |
| 2017-12-31 | 100.00% |
| 2017-09-30 | 100.00% |
| 2017-06-30 | 100.00% |
| 2017-03-31 | 100.00% |
| 2016-09-30 | 23.99% |
| 2015-09-30 | 23.55% |
